SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare plans to launch molecule for diabetes dyslipidemia: Report

19 Mar 2013 Evaluate

Cadila Healthcare, part of the ZydusCadila group, is reportedly planning to launch an indigenously developed molecule for diabetes dyslipidemia, which is expected to be called Saroglitizar. The company has been working on a new molecule since 2004. At present, the company has several molecules under its research pipeline which it hopes to bring to the market.

Recently, Zydus Cadila received tentative approval from USFDA for Doxepin Hcl tablets in the strengths of 3 mg and 6 mg. The estimated sale in 2012 as per IMS for Doxepin Hcl, which falls in the neuropsychiatry segment, was $15.5 million.

Zydus Lifesciences Share Price

939.65 0.45 (0.05%)
17-Apr-2026 09:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1689.00
Dr. Reddys Lab 1219.00
Cipla 1232.20
Zydus Lifesciences 939.65
Lupin 2327.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×